Pulmonary aspergilloma is a specific form of pulmonary aspergillosis caused by the presence of Aspergillus fungi in the lung tissue, usually occurring in the context of pre-existing lung diseases such as tuberculosis, lung cancer or chronic obstructive pulmonary disease. The condition is characterized by the formation of a granular mass (aspergilloma) containing fungal mycelium and osteoclastic cells, which can lead to a variety of symptoms including cough, sputum production and hemoptysis. Aspergilloma may be localized to one or both lungs and requires careful diagnosis and treatment.
History of the disease and interesting historical facts
The first mention of fungi of the genus Aspergillus dates back to the 11th century, but aspergilloma as a clinical condition was described only in the 20th century. A key role in the study of aspergilloma was played by the German pathologist Hugo Schimens, who in the early 1940s described this pathology and its associated clinical manifestations in detail. Interestingly, until that time, many cases of aspergillosis were interpreted as pulmonary tuberculosis due to the similarity of symptoms. It is known that aspergilloma is often associated with other lung diseases, which creates difficulties in diagnosis.
Epidemiology
Pulmonary aspergilloma is a relatively rare disease. According to various studies, its prevalence ranges from 0.03 to 2% cases among all lung diseases. The peak incidence is observed in patients with a predisposition to aspergillosis, which includes people with previous lung diseases or weakened immunity. According to statistics, men get sick more often than women, which may be due to the level of exposure to professional factors and smoking.
Genetic predisposition to this disease
Although aspergilloma is primarily caused by environmental factors, there are a number of genetic predispositions that may increase the risk of developing the disease. Certain genetic variations in the immune system, such as mutations in genes encoding interleukins and their receptors, may contribute to increased susceptibility to fungal infections. In particular, associations have been observed between aspergilloma and polymorphisms in genes involved in inflammation and response to pathogens.
Risk factors for the development of this disease
There are several factors that may increase the risk of developing pulmonary aspergilloma:
- Chronic lung diseases (eg, tuberculosis, chronic obstructive pulmonary disease);
- Conditions associated with immunodeficiency (eg, HIV/AIDS, organ transplantation);
- Smoking and long-term exposure to tobacco smoke;
- Professional exposure to mold fungi (work in agriculture, construction);
- The presence of pulmonary tumors, which may be a contingent for infection.
Diagnosis of this disease
Diagnosis of pulmonary aspergilloma involves a multi-step approach:
- The main symptoms are: cough, sputum production, hemoptysis, shortness of breath and sometimes pain;
- Laboratory tests: tests for the presence of Aspergillus antigens in serum;
- Radiological examinations: X-ray and CT scan of the lungs, which can reveal characteristic changes such as cavernous formations;
- Other types of diagnostics: bronchoscopy for biopsy purposes, as well as sputum analysis for the presence of fungi;
- Differential diagnosis: it is important to exclude tuberculosis, lung cancer and other infectious processes.
Treatment
Treatment of pulmonary aspergilloma may involve different approaches, depending on the stage of the disease and the patient's condition:
- General treatment: ensuring adequate therapy for concomitant diseases;
- Pharmacological treatment: use of antifungal drugs such as itraconazole or voriconazole;
- Surgical treatment: resection of affected lung tissue in the presence of significant lesions;
- Other treatments include immunotherapy or respiratory support.
List of medications used to treat this disease
The key drugs for the treatment of aspergilloma are:
- Itraconazole;
- Voriconazole;
- Poletryon;
- Amphotericin B;
- Caspofungin.
Disease monitoring
Monitoring the condition of a patient with aspergilloma includes regular examinations and tests:
- Control stages: dynamic monitoring of the lung condition using images;
- Prognosis: depends on timely diagnosis and treatment, but can be serious if not treated adequately;
- Complications: May include breakdown of lung tissue and development of respiratory failure.
Age-related features of the disease
Aspergilloma of the lungs can manifest itself differently depending on the age group:
- In children: the disease is rare, but can be severe;
- In adults: cases are more often registered in people over 50 years of age, especially among smokers and people with chronic lung diseases;
- In older people: Age-related changes in the immune system contribute to an increased incidence of the disease.
Questions and Answers
- What is pulmonary aspergilloma? This is a specific form of pulmonary aspergillosis associated with the accumulation of mycelium of fungi of the genus Aspergillus in the lung tissue.
- What are the main symptoms of aspergilloma? The main symptoms include cough, sputum production, hemoptysis and shortness of breath.
- What risk factors may contribute to the development of aspergilloma? Risk factors include chronic lung disease, immunodeficiency, smoking, and occupational exposure to molds.
- How is pulmonary aspergilloma diagnosed? Diagnosis includes clinical symptoms, laboratory tests for Aspergillus antigens, radiological studies, and bronchoscopy with biopsy.
- How is pulmonary aspergilloma treated? Treatment may include antifungal agents, surgical resection of affected tissue, and supportive general therapy for associated diseases.
